| 2025-01-13 |
Novartis Pharmaceuticals |
Novartis Entresto® US patent upheld by US Court of Appeals novartis.com ↗ |
| 2023-03-31 |
Novartis Pharmaceuticals |
Novartis Entresto receives positive CHMP opinion for pediatric heart failure novartis.com ↗ |
| 2021-02-16 |
Novartis Pharmaceuticals |
Novartis Entresto® granted expanded indication in chronic heart failure by FDA novartis.com ↗ |
| 2021-02-16 |
Novartis Pharmaceuticals |
Novartis Entresto® granted expanded indication in chronic heart failure by FDA novartis.com ↗ |
| 2020-12-16 |
Novartis Pharmaceuticals |
Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF novartis.com ↗ |
| 2019-11-17 |
Novartis Pharmaceuticals |
Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF novartis.com ↗ |
| 2019-09-02 |
Novartis Pharmaceuticals |
Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings novartis.com ↗ |
| 2019-09-01 |
Novartis Pharmaceuticals |
Novartis PARAGON-HF trial suggests Entresto® benefit in HFpEF patients but narrowly misses primary endpoint novartis.com ↗ |
| 2019-08-19 |
Novartis Pharmaceuticals |
Novartis to present new Entresto HFpEF and HFrEF data at ESC Congress 2019 novartis.com ↗ |
| 2018-11-11 |
Novartis Pharmaceuticals |
New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients novartis.com ↗ |
| 2018-08-25 |
Novartis Pharmaceuticals |
Novartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode novartis.com ↗ |
| 2018-05-28 |
Novartis Pharmaceuticals |
Novartis International AG: Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto® novartis.com ↗ |
| 2018-04-16 |
Novartis Pharmaceuticals |
Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes novartis.com ↗ |
| 2018-04-04 |
Novartis Pharmaceuticals |
Novartis announces JAMA Cardiology publication of data showing Entresto® improves physical and social activity in HFrEF patients versus enalapril novartis.com ↗ |
| 2017-11-12 |
Novartis Pharmaceuticals |
New Novartis Entresto® real world evidence data shows beneficial impact on quality of life in people living with heart failure novartis.com ↗ |
| 2017-03-18 |
Novartis Pharmaceuticals |
New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes novartis.com ↗ |
| 2016-11-15 |
Novartis Pharmaceuticals |
New analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and total cardiovascular deaths novartis.com ↗ |
| 2016-09-19 |
Novartis Pharmaceuticals |
Important new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients novartis.com ↗ |
| 2016-06-22 |
Novartis Pharmaceuticals |
Timely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology novartis.com ↗ |
| 2016-05-21 |
Novartis Pharmaceuticals |
Novartis' Entresto® given strong Class I recommendation in both US and EU heart failure guidelines, less than a year after regulatory approvals novartis.com ↗ |
| 2016-05-19 |
Novartis Pharmaceuticals |
Novartis announces investment in FortiHFy clinical program of Entresto® and heart failure novartis.com ↗ |
| 2016-04-02 |
Novartis Pharmaceuticals |
New analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless... novartis.com ↗ |
| 2015-11-24 |
Novartis Pharmaceuticals |
Novartis' heart failure medicine Entresto(TM) receives EU approval novartis.com ↗ |
| 2015-09-25 |
Novartis Pharmaceuticals |
Novartis' new heart failure medicine Entresto(TM) recommended by CHMP for EU approval novartis.com ↗ |
| 2015-09-18 |
Novartis Pharmaceuticals |
Swissmedic approves Novartis' new heart failure medicine Entresto(TM) novartis.com ↗ |
| 2015-07-07 |
Novartis Pharmaceuticals |
Novartis' new heart failure medicine LCZ696, now called Entresto(TM), approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization novartis.com ↗ |
|